Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gut Microbiota Targeting for Motor Complications in Parkinson's Disease
NCT04730245Phase 1Completed
- Sponsor
- Torre Médica Santé
- Start
- Jun 2018
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rifaximin in Parkinson's disease (PD), sponsored by Torre Médica Santé. Primary endpoint: Movement Disorders Society Unified Parkinson's Disease Rating Scale Part IV at 3 weeks. Started Jun 2018; status: completed.
02
Drugs
rifaximin
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04730245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04730245.